| Ytd | -16.81% | |
| 1y | 17.36% |
| Open | 4.77 | Prev Close | 4.77 | Low | 4.76 | High | 4.85 | Mkt Cap | 131.49M |
| Vol | 1.11M | Avg Vol | 1.50M | EPS | -1.75 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.23 | 200-d Avg | 6.39 | 1yr Est | 5.50 |
UNCY News
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
SAN DIEGO--(BUSINESS WIRE)---- $UNCY #Biotherapeutics--Shareholder rights law firm Robbins LLP remin
NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds
NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - September 17, 2026) - Kaplan Fox & Kilsheimer LLP announces th
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
A securities class action alleges Unicycive Therapeutics spent six months telling shareholders its O
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Unicycive Therapeutics, Inc
UNCY DEADLINE: Levi and Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securit
A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonat
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel
NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announce
San Diego, California--(Newsfile Corp. - September 15, 2026) - Shareholder rights law firm Robbins L
A securities class action alleges Unicycive Therapeutics leaned on a contract manufacturer already c
LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national sha
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
BENSALEM, Pa., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors t
Unicycive's annual report warned only that the FDA "could ask us to supplement our submissions," whi
LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announce
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the a
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again o
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therap
https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea0291789-s3_unicycive.htm
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculat
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.82) per share which missed the
The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a b
The NDA for OLC was resubmitted based on continued progress by the original third-party manufacturin